RecruitingPhase 4NCT07288801

Vitamin D for Preventing Recurrent Preeclampsia in Pregnant Women

Role of Vitamin D in Prevention of Preeclampsia Recurrence in Pregnant Women With Previous History of Preeclampsia: A Randomized Controlled Trial


Sponsor

Nishtar Medical University

Enrollment

146 participants

Start Date

Aug 9, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to find out whether giving vitamin D to pregnant women who had pre-eclampsia in a previous pregnancy helps prevent the condition from coming back. The main question it aims to answer is: Does vitamin D supplementation reduce the chance of pre-eclampsia recurring in pregnant women with a history of pre-eclampsia? To answer this question, pregnant women attending the antenatal clinic at the Department of Obstetrics and Gynaecology, Nishtar Hospital Multan will be invited to join the study. Participants will be randomly assigned to two equal groups: * Vitamin D group: will take 4,000 IU of oral vitamin D until 36 weeks of gestation. * Placebo group: will receive a pill identical in appearance, taste, and consistency but without vitamin D. While on the study medication, each woman will visit the clinic every two weeks. At each visit, her blood pressure will be measured, and if it is 140/90 mmHg or higher, a urine test will check for protein to identify pre-eclampsia as per hospital protocol. Any diagnosis of pre-eclampsia will lead to standard care, and the outcome will be recorded. At the end, researchers will compare how many women in each group developed recurrent pre-eclampsia. This study will help answer whether vitamin D supplementation can safely reduce the risk of pre-eclampsia returning in women with a prior history - a question important for improving pregnancy outcomes and maternal health.


Eligibility

Sex: FEMALEMin Age: 20 YearsMax Age: 45 Years

Inclusion Criteria1

  • Gestational age ≥ 20-weeks (on LMP method) ' - Past medical history of pre-eclampsia

Exclusion Criteria2

  • Pre-existing hypertension, cardiac diseases, renal disease, thyrotoxicosis (on history and medical record)
  • Women presenting with intra-uterine death of the fetus.

Interventions

DRUGVitamin D

4000 IU of vitamin D will be given orally, once daily till 36-weeks of gestation

DRUGPlacebo and standard of care

Look, smell and taste alike oil emulsion drops, same number, till 36-weeks of gestation


Locations(1)

Nishtar Medical University and Hospital

Multan, Punjab Province, Pakistan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07288801


Related Trials